Analyst Research

Report Title Price
Provider: GlobalData
$125.00
Provider: Finlabo SIM Spa
$10.00
Provider: ValuEngine, Inc.
$25.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Food and Drug Administration Grants Priority Review of Bayer AG's Radium Ra 223 Dichloride for Prostate Cancer-Dow Jones


Wednesday, 13 Feb 2013 03:18pm EST 

Dow Jones reported that Bayer AG's new drug application for its oncology compound, Radium Ra 223 Dichloride, was granted priority review by the United States Food and Drug Administration (FDA). The compound is under review for the treatment of castration-resistant prostate cancer in patients with bone metastases. The FDA grants priority review to medicines that provide a treatment where little or no adequate therapy exists and aims to complete its review within six months of the 60-day filing receipt rather than the standard 12-month review. 

Company Quote

115.2
-0.2 -0.17%
23 Dec 2014